RF
BMRN icon

Rossby Financial’s BioMarin Pharmaceuticals BMRN Stock Holding History

Rossby Financial’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.13K Buy
142
+14
+11% +$767 ﹤0.01% 1245
2026
Q1 		$7.33K Buy
128
+82
+178% +$4.78K ﹤0.01% 1365
2025
Q4 		$2.73K Buy
46
+23
+100% +$1.25K ﹤0.01% 1280
2025
Q3 		$1.26K Buy
+23
New +$1.31K ﹤0.01% 1240

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Rossby Financial's BMRN Position: Q2 2026 in Review

Rossby Financial increased its BioMarin Pharmaceuticals (BMRN) stake by 11% in Q2 2026, buying an estimated $767 and bringing the position to 142 shares worth $8.13K. The position accounts for ﹤0.01% of the portfolio, ranked #1245.

Rossby Financial first reported a position in BMRN in Q3 2025 and has held it in 4 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Rossby Financial held 142 shares of BioMarin Pharmaceuticals worth $8.13K as of Q2 2026.
  • Rossby Financial bought 14 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $767.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Rossby Financial's portfolio in Q2 2026, its #1245 holding.
  • Rossby Financial first reported a position in BioMarin Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Rossby Financial's 13F filing for Q2 2026, filed 4 Aug 2026.